Seven of the 15 studies provided complete data regarding the number of patients with elevated PSA after treatment; however, 2 studies reported zero patients in the control groups,21,22 and thus the 2 studies were excluded from the analysis because zero cannot be used to calculate an OR (Figure 3). In 6 studies, testosterone was administered transdermally, in 7 intramuscularly (IM), and in 2 orally, and the duration of treatment ranged from 3 to 12 months. Testosterone replacement therapy does not increase PSA levels in men being treated for hypogonadism, except when it is given IM and even the increase with IM administration is minimal. After initially identifying 511 articles, 15 studies with a total of 739 patients that received testosterone replacement and 385 controls were included. When the prostate is growing, testosterone is converted into dihydrotestosterone (DHT), which is the androgen receptor's major activator 13,14. Clinical and laboratory features in men with and those without prostate cancer We classified the men as hypogonadal if their serum testosterone level was 11.|Most medical guidelines recommend that men at high risk of prostate cancer (due to age, family history, ethnicity, or prior evidence of high blood PSA levels) be counseled on the risks and benefits of PSA testing, and be offered access to screening tests. Men with PSA levels above 4 ng/mL are at increased risk – around 1 in 4 will develop prostate cancer – and are often referred for a prostate biopsy. Those whose cancer spreads beyond the prostate are treated with hormone therapy which reduces levels of the androgens (masculinizing sex hormones) which prostate cells need to survive. Those with high levels of PSA in their blood are at increased risk for developing prostate cancer. The frequency of prostate cancer screening during TRT should be determined by your doctor, based on your individual risk factors, including age, family history, and PSA levels.|However, in general, anything over 10 ng/mL is linked to a 50% chance of prostate cancer, and the doctors will order more tests. The result of our study demonstrated that raising serum T levels of normal nude mice without PCa did not have any effect on serum PSA levels. Normal serum T levels in adult men are between 2.4 and 9.5 ng ml−1(Mayo Clinic). In order to avoid tumor volume interference, besides analyzing the data by standardizing the PSA levels by tumor volumes as above, we also chose 10 pairs of tumor caring mice from groups before and after T pellet implantation. Serum T (a), PSA (b), and tumor volume standardized PSA levels (c) of LNCaP tumor caring mice before and 1 week after 2 mg T pellet implantation.|South Asia, Central Asia, and sub-Saharan Africa have the lowest incidence of prostate cancer; though incidence is increasing quickly in these regions. Due to this, prostate cancer rates are generally higher in parts of the world with higher life expectancy, which also tend to be areas with higher gross domestic product and higher human development index. One in eight men are diagnosed with prostate cancer in their lifetime, and around one in forty die of the disease. Around 1.2 million new cases of prostate cancer are diagnosed each year, and more than 350,000 people die of the disease annually. The transition from castrate-sensitive to castrate-resistant prostate cancer is also accompanied by the acquisition of various gene mutations. In advanced tumors, cells can develop the ability to detach from their original tissue site, and evade the immune system.} The risk of developing prostate cancer increases with age; the average age of diagnosis is 67. Most men diagnosed have low-risk tumors confined to the prostate; 99% of them survive more than 10 years from their diagnoses. This most-advanced stage of the disease, called castration-resistant prostate cancer, is treated with continued hormone therapy alongside the chemotherapy drug docetaxel. Abnormal growth of the prostate tissue is usually detected through screening tests, typically blood tests that check for prostate-specific antigen (PSA) levels. No, the method of TRT administration doesn’t directly impact the risk of prostate cancer. Yes, TRT should be stopped immediately if prostate cancer is diagnosed during treatment. Men with a family history of prostate cancer should discuss the risks and benefits of TRT with their doctor. Regular vigorous exercise may reduce one's chance of developing advanced prostate cancer, as can several dietary interventions. Pharmacogenomic differences in testosterone metabolism between East Asian men and white American and European populations may also contribute to observed differences in disease incidence and response to androgen deprivation therapy. In contrast to men of African descent, East Asian men have among the lowest rates of prostate cancer globally. Together, known gene variants are estimated to cause around 25% of prostate cancer cases, including 40% of early-onset prostate cancers. GnRH agonists cause a brief rise in testosterone levels at treatment initiation, which can worsen disease in people with significant symptoms of metastases. Various drugs are used to lower androgen levels by blocking the synthesis or action of testosterone, the primary androgen. People with high or rising PSA levels are often offered another round of radiation therapy directed at the former tumor site. At least half of men remain on active surveillance, never requiring more direct treatment for their prostate tumors. This program continues until increases in PSA levels, Gleason grade, or tumor size indicate a higher-risk tumor that may require intervention. DHT had the same effects on the PSA production in LNCaP cells (figure not shown). When T was added to the fresh serum-free medium on day 4, PSA production resumed and was detected on day 5 (Figure 1). Male nude/nude athymic mice (Jackson Lab, ) were used in this experiment for LNCaP cell tumor xenografts development. Different concentrations of T or dihydrotestosterone (DHT) (0, 0.5, 1, 2, 4, 8, and 16 ng ml−1) were added to different wells on day 4 after medium change. After 48 h, medium was changed to fresh serum free medium (date was designed as day 0). LNCaP cells were seeded 15,000 per well (each sample in triples) in RPMI-1640 medium supplemented with 10% FBS. This may have clinical implications when screening PSA in men, who have occult PCa.
